c107769.htm - Generated by SEC Publisher for SEC Filing

 

 

 

 


 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549
 

________________

FORM 6-K

________________

 

REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

January 2, 2013

________________

 

        NOVO NORDISK A/S        
(Exact name of Registrant as specified in its charter)

Novo Allé
DK- 2880, Bagsvaerd
Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F [X]     

     Form 40-F [  ]

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes [  ]     

      No [X]

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____________________

 

 

 


 

 

logo.gif

 

Status regarding Novo Nordisk's holding of its own shares (31 December 2012)

  

Bagsværd, Denmark, 2 January 2013 – In continuation of the company's announcements dated 9 August 2012 and 9 November 2012 concerning planned share repurchase programmes, and pursuant to Section 204.25 of the New York Stock Exchange Listed Company Manual, this is to report that Novo Nordisk A/S (NYSE: NVO) and its wholly-owned affiliates on 31 December 2012 owned 17,416,676 of its own B shares of DKK 1, corresponding to a total nominal value of DKK 17,416,676 or 3.1% of the total share capital.

  

In the fourth quarter of 2012 a total of 1,359,148 B shares were repurchased, and 316,577 B shares were disposed of to employees in connection with employee incentive programmes.

  

  

Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 33,900 employees in 75 countries, and markets its products in more than 190 countries. Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com

  

  

Further information

Media:

Anne Margrethe Hauge

+45 4442 3450

amhg@novonordisk.com

Ken Inchausti (US)

+1 609 514 8316

kiau@novonordisk.com

Investors:

Kasper Roseeuw Poulsen

+45 4442 4303

krop@novonordisk.com

Frank Daniel Mersebach

+45 4442 0604

fdni@novonordisk.com

Lars Borup Jacobsen

+45 3075 3479

lbpj@novonordisk.com

Jannick Lindegaard (US)

+1 609 786 4575

jlis@novonordisk.com

 

 

Novo Nordisk A/S

Novo Allé

Telephone:

Internet:

Investor Relations

2880 Bagsværd

+45 4444 8888

www.novonordisk.com

Denmark

Telefax:

CVR no:

 

+45 4444 6626

24 25 67 90

 

 

 

Company announcement No 2 / 2013

 

 

 


 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: January 2, 2013

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer